Sanghyuck Nam Promoted to OncoPep Chief Financial Officer

Cambridge, MA – June 14, 2022 – OncoPep, Inc. has named Sanghyuck Nam Chief Financial Officer effective May 11th. In addition to his responsibilities for OncoPep’s financial controls and planning, Nam will be integral to continuing the development of the company’s relationships with businesses and investors in Korea. Hired in 2020 as OncoPep’s Director of Korea Investor Relations, Nam will also continue to serve as the primary liaison between OncoPep and its Korean legal, accounting and audit firms, the Korean Securities Depository, the Korea Exchange (KRX), and the company’s Korean IPO underwriter, Shinhan Financial Group.

“Sanghyuck’s appointment to CFO was a natural step in the progression of our financial standing in Korea with investors and investment professionals,” said Arthur Becker, CEO of OncoPep. “The promotion of Sang to the CFO position both recognizes his excellent work to date and further solidifies the relationships he has built with the Korean financial and biotech community and will enable OncoPep to further advance these relationships that have proven to be a life blood to our efforts.”

Nam has over 20 years of experience international financial business and markets serving as CFO for several international construction companies based in Abu Dhabi and Singapore, as well as working as a financial analyst for a multinational IT corporation.

“I am gratified to be given the trust to act as OncoPep’s financial steward,” Nam said. “I will continue to work closely with the US team and the Korean investment professionals to advance OncoPep’s goals in Korea.

Nam majored in finance and earned his BA from the Baruch college, Zicklin school of business and passed his CFA exam in 2009.

About OncoPep, Inc:
OncoPep, Inc. is developing novel immunotherapeutics to prevent the progression of cancer, extend survival, and restore the quality of life of patients. OncoPep’s lead program, PVX-410, is an investigational, multi-peptide therapeutic vaccine being evaluated to treat smoldering multiple myeloma and triple-negative breast cancer by stimulating an immune response against cancer cells.